Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-MRSA beta-lactams in development.

Malcolm G P Page1

  • 1Basilea Pharmaceutica Ltd., Grenzacherstrasse 487, CH-4005 Basel, Switzerland. malcolm.page@basilea.com

Current Opinion in Pharmacology
|August 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A unified annotation scheme for class D β-lactamases.

Antimicrobial agents and chemotherapy·2025
Same author

Siderophore cephalosporins.

EcoSal Plus·2025
Same author

Revitalizing antibiotic discovery and development through in vitro modelling of in-patient conditions.

Nature microbiology·2024
Same author

Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors.

Nature chemistry·2021
Same author

Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes.

Antimicrobial agents and chemotherapy·2020
Same author

Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C β-Lactamase from <i>Escherichia coli</i>.

Biomolecules·2020
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

Ceftobiprole medocaril, an advanced anti-MRSA drug, showed non-inferiority to vancomycin in a Phase III trial. New trials are underway for other MRSA-fighting cephalosporins and carbapenems.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) presents a significant public health challenge.
  • Beta-lactam antibiotics are crucial for treating bacterial infections, but resistance is increasing.
  • Novel anti-MRSA agents are urgently needed to combat resistant pathogens.

Purpose of the Study:

  • To evaluate the efficacy and safety of ceftobiprole medocaril, a novel anti-MRSA beta-lactam.
  • To assess the clinical development progress of other broad-spectrum cephalosporins and carbapenems with anti-MRSA activity.

Main Methods:

  • Phase III clinical trial comparing ceftobiprole medocaril to vancomycin.
  • Initiation of Phase II clinical trials for PPI0903 and RO4908643.

Related Experiment Videos

Main Results:

  • Ceftobiprole medocaril demonstrated non-inferiority to vancomycin in its Phase III trial.
  • Phase II trials for PPI0903 and RO4908643 have commenced.

Conclusions:

  • Ceftobiprole medocaril represents a promising therapeutic option against MRSA infections.
  • Ongoing clinical trials for PPI0903 and RO4908643 will further expand treatment options for MRSA.